Alimera announces FDA acceptance of ILUVIEN for treatment of diabetic macular edema Alimera Sciences, Inc. , a pharmaceutical firm that specializes in the extensive research, commercialization and advancement of prescription ophthalmic pharmaceuticals, today announced that the U.S. Alimera intends to begin offering ILUVIEN in the U currently.S. In the first quarter of 2015. We have become excited by this information late today and by the broader label ILUVIEN has been granted by the FDA, stated Dan Myers, president and chief executive officer of Alimera. We plan to issue a more complete announcement on Monday morning. .19. The meeting was attended by a lot more than 150 venture capitalists, seasoned biotech business and entrepreneurs development executives from the biopharma industry. Judging committees evaluated presentations from two dozen university experts before choosing the winners. The aim of the awards is certainly to rate the translation of promising analysis into commercial application. Awarded in 2010 First, the LIFE Prizes are two grants funded by the Maryland Biotechnology Center, Johns Hopkins and the University of Maryland to help advance research in biopharma and biotech, medical products, or diagnostics that have great potential for commercial application. Wong will use the funding to develop technology that will aid in the safer delivery of radiation therapy.